VPS52 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the VPS52 (Vacuolar Protein Sorting 52) protein, a key component of the Golgi-associated retrograde protein (GARP) complex. VPS52 is involved in vesicular trafficking, particularly in the retrograde transport of proteins from endosomes to the trans-Golgi network (TGN). The GARP complex, which includes VPS52 along with other subunits such as VPS53 and VPS54, plays an essential role in maintaining the proper sorting and recycling of proteins, ensuring that they reach their correct intracellular destinations. By inhibiting VPS52, these compounds interfere with the function of the GARP complex, disrupting intracellular trafficking pathways and protein recycling processes that are critical for cellular homeostasis and organelle function.
The mechanism of action for VPS52 inhibitors typically involves binding to functional regions of the protein that are necessary for its interaction with other GARP complex components or its engagement with vesicular membranes. This inhibition impairs the complex's ability to mediate retrograde transport, resulting in disruptions in the flow of proteins between the endosomes and the Golgi apparatus. Such interference can affect a variety of cellular processes, including membrane protein recycling, lysosome function, and the maintenance of Golgi structure. Researchers use VPS52 inhibitors to study the specific roles of VPS52 in vesicle trafficking and to explore how alterations in this pathway influence broader aspects of cellular organization and function. These inhibitors provide insights into the molecular mechanisms governing intracellular transport and highlight the critical role of protein sorting systems in maintaining the dynamic balance of cellular processes across various compartments.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
May alter lysosomal function, indirectly affecting VPS52-associated processes. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Could disrupt Golgi apparatus function, indirectly influencing VPS52 activity. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Might alter Golgi and endosomal compartments, affecting VPS52 function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Could inhibit N-linked glycosylation, affecting proteins interacting with VPS52. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Might disrupt microtubule dynamics, affecting VPS52-related transport processes. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Could affect microtubule polymerization, influencing VPS52-related activities. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Might inhibit dynamin, affecting endocytic pathways involving VPS52. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Could disrupt actin filaments, influencing cellular processes involving VPS52. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Could inhibit vacuolar-type H+-ATPase, affecting lysosomal function involving VPS52. | ||||||
Concanamycin B | 81552-33-2 | sc-221434 sc-221434A | 100 µg 500 µg | $463.00 $1569.00 | 2 | |
Might inhibit vacuolar-type H+-ATPase, affecting VPS52-related processes. | ||||||